Protara Therapeutics, Inc. (TARA): Price and Financial Metrics


Protara Therapeutics, Inc. (TARA): $3.49

0.18 (+5.44%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TARA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TARA Stock Price Chart Interactive Chart >

Price chart for TARA

TARA Price/Volume Stats

Current price $3.49 52-week high $11.10
Prev. close $3.31 52-week low $2.72
Day low $3.40 Volume 11,100
Day high $3.60 Avg. volume 36,985
50-day MA $4.15 Dividend yield N/A
200-day MA $5.86 Market Cap 39.27M

Protara Therapeutics, Inc. (TARA) Company Bio


Protara Therapeutics, Inc. operates as a biotech company. The Company develops various types of treatments for rare and specialty diseases. Protara Therapeutics serves customers in the State of New York.


TARA Latest News Stream


Event/Time News Detail
Loading, please wait...

TARA Latest Social Stream


Loading social stream, please wait...

View Full TARA Social Stream

Latest TARA News From Around the Web

Below are the latest news stories about Protara Therapeutics Inc that investors may wish to consider to help them evaluate TARA as an investment opportunity.

Protara Therapeutics to Participate in the Guggenheim Healthcare Talks 2022 Oncology Conference

NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the Guggenheim Healthcare Talks 2022 Oncology Conference on February 9, 2022 at 4:00 PM ET. A live webcast of the fireside chat can be accessed by visiting the Events and Presentations section of the Company’s website: https:/

Yahoo | February 1, 2022

Protara Therapeutics Announces Appointment of Jathin Bandari, M.D. as Chief Medical Officer

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the appointment of Jathin Bandari, M.D., as Chief Medical Officer. Dr. Bandari is a practicing urologic oncologist, recently serving at the University of Rochester where he specialized in both minimally invasive urologic oncology and advanced open pelvic retroperitoneal cancer surgery, an

Yahoo | January 10, 2022

Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that management will present at the H.C. Wainwright BioConnect Virtual Conference being held from January 10-13, 2022. The prerecorded presentation will become available on Monday, January 10, 2022 at 7:00am ET and can be accessed by visiting the Events and Pr

Yahoo | January 4, 2022

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Yahoo | December 8, 2021

Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview

– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End – – Strong Cash, Cash Equivalents, and Marketable Debt Securities of $138.4M as of September 30, 2021 – NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, tod

Yahoo | November 4, 2021

Read More 'TARA' Stories Here

TARA Price Returns

1-mo -7.43%
3-mo -24.30%
6-mo -50.14%
1-year -63.19%
3-year -79.23%
5-year -93.02%
YTD -48.30%
2021 -72.12%
2020 47.62%
2019 -81.94%
2018 19.47%
2017 0.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6818 seconds.